felodipine (Plendil)

Title: felodipine (Plendil)Category: MedicationsCreated: 4/3/1999 12:00:00 AMLast Editorial Review: 7/8/2016 12:00:00 AM
Source: MedicineNet High Blood Pressure General - Category: Cardiology Source Type: news

Related Links:

Conclusions. Seven years following PFT, the patient gained limb strength with a functional elbow and wrist, although with diminished digital dexterity and sensation. Based on data presented by other programs and our own experience, PFT is indicated for select patients.
Source: Transplantation - Category: Transplant Surgery Tags: Original Clinical Science—General Source Type: research
Pulmonary endarterectomy (PEA) is a curative surgical option for patients with chronic thromboembolic pulmonary hypertension (CTEPH), a disease resulting from chronic pulmonary thromboembolism. The role of sarcopenia (i.e. low skeletal muscle mass) has been shown to be associated with adverse outcomes in surgical populations, but its significance with PEA remains unknown. We sought to evaluate the association of sarcopenia with measures of CTEPH severity and post-operative hospital outcomes.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (57) Source Type: research
Pulmonary endarterectomy (PEA) is curative for suitable chronic thromboembolic pulmonary hypertension (CTEPH) patients. Careful anticoagulation prevents postoperative bleeding and thromboembolic recurrence. Heparinization is often guided by aPTT but it can be influenced by Factor VIII - a coagulation factor elevated in CTEPH. Anti-Xa-guided anticoagulation is less affected by other factors. We investigated the correlation between aPTT and Anti-Xa after PEA and the impact of coagulation factors.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (56) Source Type: research
Pulmonary artery sarcoma (PAS) is an exceedingly rare disease with historically poor survival. PAS is often mistaken for chronic thromboembolic pulmonary hypertension (CTEPH) owing to similarities in clinical presentation. Controversy exists regarding need to definitively differentiate PAS from CTEPH prior to surgical therapy. Furthermore lung resection would seem inferior palliation to tumor endarterectomy in a predominantly bilateral disease dominated by hemodynamic compromise.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (55) Source Type: research
The REVEAL risk score (RRS) predicts 1-year survival in patients with pulmonary arterial hypertension; it also improved with riociguat in patients with inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) in the Phase III CHEST-1 study, and predicted survival and clinical worsening-free survival (CWFS) in the long-term extension CHEST-2. RRS 2.0, an updated RRS, was developed based on modified point values, cut-offs, and variables. This post hoc analysis aimed to validate RRS 2.0 in the CHEST database (a population not derived from REVEAL), as done previously, and assess if the tool disc...
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (54) Source Type: research
Chronic thromboembolic pulmonary hypertension (CTEPH), is a progressive condition characterized by persistent elevation in pulmonary artery pressure due to thromboembolic occlusion of the pulmonary arteries. Little is known about the cells that make up the cast of pulmonary endarterectomy (PEA) and its immune microenvironment. Here we report a map of the cellular landscape of the human PEA specimen using single-cell RNA sequencing.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (53) Source Type: research
Pulmonary endarterectomy (PEA) is established as the recommended treatment for chronic thromboembolic pulmonary hypertension (CTEPH). The aim of this work was to review outcomes by era at a high-volume national PEA centre.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (52) Source Type: research
Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by organized thrombi in the pulmonary arteries leading to right heart failure and death. Impaired angiogenesis and systemic inflammation could be involved in the pathophysiology of this disease. The aim of this study was to determine the angiogenic expression profile in patients with CTEPH.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (51) Source Type: research
We present a case of severe pulmonary hypertension in the setting of perimembranous VSD and severe AS.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (24) Source Type: research
Pulmonary veno-occlusive disease (PVOD) is a rare cause of pulmonary hypertension. In PVOD the pulmonary venous vessels are obliterated resulting in obstructive pulmonary vascular disease, increase in pulmonary vascular resistance, right heart failure and death. Pulmonary hypertension is the most common reason for lung transplant in infants. Lung transplant is the only therapy for PVOD. Prolonged intubation, deconditioning and extra corporeal life support are associated with poor outcomes after lung transplant.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (23) Source Type: research
More News: Cardiology | Felodipine | Hypertension